04866nas a2200949 4500008004100000022001400041245013400055210006900189260001200258300001300270490000700283520220500290653000902495653001402504653001502518653001902533653003002552653001702582653001102599653001602610653003302626653001102659653001102670653001402681653000902695653001602704653002402720653001602744653001102760653001802771100002102789700001902810700002002829700003002849700001802879700002002897700001902917700002202936700001702958700001602975700002202991700001903013700001903032700002003051700002503071700002103096700002803117700002403145700001803169700002603187700002103213700002203234700002403256700002303280700001903303700001403322700002003336700001903356700001503375700001703390700002203407700002403429700001703453700002603470700002103496700002403517700003003541700002203571700001203593700002103605700002003626700002603646700002103672700001803693700001803711700002103729700002403750700002503774710002403799710005703823856003603880 2018 eng d a1549-167600aFatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies.0 aFatty acid biomarkers of dairy fat consumption and incidence of c2018 10 ae10026700 v153 a
BACKGROUND: We aimed to investigate prospective associations of circulating or adipose tissue odd-chain fatty acids 15:0 and 17:0 and trans-palmitoleic acid, t16:1n-7, as potential biomarkers of dairy fat intake, with incident type 2 diabetes (T2D).
METHODS AND FINDINGS: Sixteen prospective cohorts from 12 countries (7 from the United States, 7 from Europe, 1 from Australia, 1 from Taiwan) performed new harmonised individual-level analysis for the prospective associations according to a standardised plan. In total, 63,682 participants with a broad range of baseline ages and BMIs and 15,180 incident cases of T2D over the average of 9 years of follow-up were evaluated. Study-specific results were pooled using inverse-variance-weighted meta-analysis. Prespecified interactions by age, sex, BMI, and race/ethnicity were explored in each cohort and were meta-analysed. Potential heterogeneity by cohort-specific characteristics (regions, lipid compartments used for fatty acid assays) was assessed with metaregression. After adjustment for potential confounders, including measures of adiposity (BMI, waist circumference) and lipogenesis (levels of palmitate, triglycerides), higher levels of 15:0, 17:0, and t16:1n-7 were associated with lower incidence of T2D. In the most adjusted model, the hazard ratio (95% CI) for incident T2D per cohort-specific 10th to 90th percentile range of 15:0 was 0.80 (0.73-0.87); of 17:0, 0.65 (0.59-0.72); of t16:1n7, 0.82 (0.70-0.96); and of their sum, 0.71 (0.63-0.79). In exploratory analyses, similar associations for 15:0, 17:0, and the sum of all three fatty acids were present in both genders but stronger in women than in men (pinteraction < 0.001). Whereas studying associations with biomarkers has several advantages, as limitations, the biomarkers do not distinguish between different food sources of dairy fat (e.g., cheese, yogurt, milk), and residual confounding by unmeasured or imprecisely measured confounders may exist.
CONCLUSIONS: In a large meta-analysis that pooled the findings from 16 prospective cohort studies, higher levels of 15:0, 17:0, and t16:1n-7 were associated with a lower risk of T2D.
10aAged10aAustralia10aBiomarkers10aDairy Products10aDiabetes Mellitus, Type 210aDietary Fats10aEurope10aFatty Acids10aFatty Acids, Monounsaturated10aFemale10aHumans10aIncidence10aMale10aMiddle Aged10aProspective Studies10aSex Factors10aTaiwan10aUnited States1 aImamura, Fumiaki1 aFretts, Amanda1 aMarklund, Matti1 aKorat, Andres, V Ardisson1 aYang, Wei-Sin1 aLankinen, Maria1 aQureshi, Waqas1 aHelmer, Catherine1 aChen, Tzu-An1 aWong, Kerry1 aBassett, Julie, K1 aMurphy, Rachel1 aTintle, Nathan1 aYu, Chaoyu, Ian1 aBrouwer, Ingeborg, A1 aChien, Kuo-Liong1 aFrazier-Wood, Alexis, C1 aDel Gobbo, Liana, C1 aDjoussé, Luc1 aGeleijnse, Johanna, M1 aGiles, Graham, G1 ade Goede, Janette1 aGudnason, Vilmundur1 aHarris, William, S1 aHodge, Allison1 aHu, Frank1 aKoulman, Albert1 aLaakso, Markku1 aLind, Lars1 aLin, Hung-Ju1 aMcKnight, Barbara1 aRajaobelina, Kalina1 aRiserus, Ulf1 aRobinson, Jennifer, G1 aSamieri, Cecilia1 aSiscovick, David, S1 aSoedamah-Muthu, Sabita, S1 aSotoodehnia, Nona1 aSun, Qi1 aTsai, Michael, Y1 aUusitupa, Matti1 aWagenknecht, Lynne, E1 aWareham, Nick, J1 aWu, Jason, HY1 aMicha, Renata1 aForouhi, Nita, G1 aLemaitre, Rozenn, N1 aMozaffarian, Dariush1 aInterAct Consortium1 aFatty Acids and Outcomes Research Consortium (FORCE) uhttps://chs-nhlbi.org/node/804105879nas a2201189 4500008004100000022001400041245009700055210006900152260001600221300001400237490000800251520248600259100002002745700001802765700002102783700002402804700001902828700002202847700001602869700001902885700002002904700002302924700001702947700002902964700002302993700002903016700002003045700002203065700002003087700002203107700001703129700002103146700002003167700002003187700001603207700001803223700001403241700001603255700002303271700002503294700001903319700002303338700002103361700001803382700001803400700002403418700002203442700002103464700002103485700002603506700001903532700001803551700002003569700002403589700001903613700002303632700002203655700002303677700001903700700001703719700002103736700002403757700001903781700001803800700001903818700001903837700001903856700001703875700001503892700001803907700001503925700002203940700001803962700002403980700001704004700002004021700001504041700002504056700002104081700003004102700002104132700002204153700001704175700001204192700002204204700002104226700002504247700002504272700002004297700002004317700002904337700001804366700002004384700001904404700001904423700001804442700002404460700002504484700001704509710012704526856003604653 2019 eng d a1524-453900aBiomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality.0 aBiomarkers of Dietary Omega6 Fatty Acids and Incident Cardiovasc c2019 May 21 a2422-24360 v1393 aBACKGROUND: Global dietary recommendations for and cardiovascular effects of linoleic acid, the major dietary omega-6 fatty acid, and its major metabolite, arachidonic acid, remain controversial. To address this uncertainty and inform international recommendations, we evaluated how in vivo circulating and tissue levels of linoleic acid (LA) and arachidonic acid (AA) relate to incident cardiovascular disease (CVD) across multiple international studies.
METHODS: We performed harmonized, de novo, individual-level analyses in a global consortium of 30 prospective observational studies from 13 countries. Multivariable-adjusted associations of circulating and adipose tissue LA and AA biomarkers with incident total CVD and subtypes (coronary heart disease, ischemic stroke, cardiovascular mortality) were investigated according to a prespecified analytic plan. Levels of LA and AA, measured as the percentage of total fatty acids, were evaluated linearly according to their interquintile range (ie, the range between the midpoint of the first and fifth quintiles), and categorically by quintiles. Study-specific results were pooled using inverse-variance-weighted meta-analysis. Heterogeneity was explored by age, sex, race, diabetes mellitus, statin use, aspirin use, omega-3 levels, and fatty acid desaturase 1 genotype (when available).
RESULTS: In 30 prospective studies with medians of follow-up ranging 2.5 to 31.9 years, 15 198 incident cardiovascular events occurred among 68 659 participants. Higher levels of LA were significantly associated with lower risks of total CVD, cardiovascular mortality, and ischemic stroke, with hazard ratios per interquintile range of 0.93 (95% CI, 0.88-0.99), 0.78 (0.70-0.85), and 0.88 (0.79-0.98), respectively, and nonsignificantly with lower coronary heart disease risk (0.94; 0.88-1.00). Relationships were similar for LA evaluated across quintiles. AA levels were not associated with higher risk of cardiovascular outcomes; in a comparison of extreme quintiles, higher levels were associated with lower risk of total CVD (0.92; 0.86-0.99). No consistent heterogeneity by population subgroups was identified in the observed relationships.
CONCLUSIONS: In pooled global analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major cardiovascular events. These results support a favorable role for LA in CVD prevention.
1 aMarklund, Matti1 aH Y Wu, Jason1 aImamura, Fumiaki1 aDel Gobbo, Liana, C1 aFretts, Amanda1 ade Goede, Janette1 aShi, Peilin1 aTintle, Nathan1 aWennberg, Maria1 aAslibekyan, Stella1 aChen, Tzu-An1 aOtto, Marcia, C de Olive1 aHirakawa, Yoichiro1 aEriksen, Helle, Højmark1 aKröger, Janine1 aLaguzzi, Federica1 aLankinen, Maria1 aMurphy, Rachel, A1 aPrem, Kiesha1 aSamieri, Cecilia1 aVirtanen, Jyrki1 aWood, Alexis, C1 aWong, Kerry1 aYang, Wei-Sin1 aZhou, Xia1 aBaylin, Ana1 aBoer, Jolanda, M A1 aBrouwer, Ingeborg, A1 aCampos, Hannia1 aChaves, Paulo, H M1 aChien, Kuo-Liong1 ade Faire, Ulf1 aDjoussé, Luc1 aEiriksdottir, Gudny1 aEl-Abbadi, Naglaa1 aForouhi, Nita, G1 aGaziano, Michael1 aGeleijnse, Johanna, M1 aGigante, Bruna1 aGiles, Graham1 aGuallar, Eliseo1 aGudnason, Vilmundur1 aHarris, Tamara1 aHarris, William, S1 aHelmer, Catherine1 aHellenius, Mai-Lis1 aHodge, Allison1 aHu, Frank, B1 aJacques, Paul, F1 aJansson, Jan-Håkan1 aKalsbeek, Anya1 aKhaw, Kay-Tee1 aKoh, Woon-Puay1 aLaakso, Markku1 aLeander, Karin1 aLin, Hung-Ju1 aLind, Lars1 aLuben, Robert1 aLuo, Juhua1 aMcKnight, Barbara1 aMursu, Jaakko1 aNinomiya, Toshiharu1 aOvervad, Kim1 aPsaty, Bruce, M1 aRimm, Eric1 aSchulze, Matthias, B1 aSiscovick, David1 aNielsen, Michael, Skjelbo1 aSmith, Albert, V1 aSteffen, Brian, T1 aSteffen, Lyn1 aSun, Qi1 aSundström, Johan1 aTsai, Michael, Y1 aTunstall-Pedoe, Hugh1 aUusitupa, Matti, I J1 avan Dam, Rob, M1 aVeenstra, Jenna1 aVerschuren, W, M Monique1 aWareham, Nick1 aWillett, Walter1 aWoodward, Mark1 aYuan, Jian-Min1 aMicha, Renata1 aLemaitre, Rozenn, N1 aMozaffarian, Dariush1 aRiserus, Ulf1 aCohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCE) uhttps://chs-nhlbi.org/node/804703731nas a2200973 4500008004100000022001400041245010000055210006900155260001500224300000900239490000700248520100600255653000901261653002201270653001901292653002501311653001101336653002201347653001101369653000901380653001601389653002501405653002401430653002301454653001701477100002301494700002201517700002101539700001601560700003001576700002001606700001801626700002201644700003001666700001701696700002301713700002301736700002201759700002001781700002201801700002101823700002301844700001601867700002301883700002501906700002101931700002401952700002101976700002601997700002102023700002402044700002202068700001902090700002102109700001802130700001902148700001502167700002102182700001902203700001802222700001802240700001702258700002402275700001602299700002002315700001702335700002602352700002402378700002202402700002102424700001602445700002002461700002102481700002502502700002002527700001802547700001402565700001202579700002402591700002402615700002502639710005702664856003602721 2021 eng d a2041-172300aBlood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies.0 aBlood n3 fatty acid levels and total and causespecific mortality c2021 04 22 a23290 v123 aThe health effects of omega-3 fatty acids have been controversial. Here we report the results of a de novo pooled analysis conducted with data from 17 prospective cohort studies examining the associations between blood omega-3 fatty acid levels and risk for all-cause mortality. Over a median of 16 years of follow-up, 15,720 deaths occurred among 42,466 individuals. We found that, after multivariable adjustment for relevant risk factors, risk for death from all causes was significantly lower (by 15-18%, at least p < 0.003) in the highest vs the lowest quintile for circulating long chain (20-22 carbon) omega-3 fatty acids (eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids). Similar relationships were seen for death from cardiovascular disease, cancer and other causes. No associations were seen with the 18-carbon omega-3, alpha-linolenic acid. These findings suggest that higher circulating levels of marine n-3 PUFA are associated with a lower risk of premature death.
10aAged10aAged, 80 and over10aCause of Death10aFatty Acids, Omega-310aFemale10aFollow-Up Studies10aHumans10aMale10aMiddle Aged10aMortality, Premature10aProspective Studies10aProtective Factors10aRisk Factors1 aHarris, William, S1 aTintle, Nathan, L1 aImamura, Fumiaki1 aQian, Frank1 aKorat, Andres, V Ardisson1 aMarklund, Matti1 aDjoussé, Luc1 aBassett, Julie, K1 aCarmichael, Pierre-Hugues1 aChen, Yun-Yu1 aHirakawa, Yoichiro1 aKüpers, Leanne, K1 aLaguzzi, Federica1 aLankinen, Maria1 aMurphy, Rachel, A1 aSamieri, Cecilia1 aSenn, Mackenzie, K1 aShi, Peilin1 aVirtanen, Jyrki, K1 aBrouwer, Ingeborg, A1 aChien, Kuo-Liong1 aEiriksdottir, Gudny1 aForouhi, Nita, G1 aGeleijnse, Johanna, M1 aGiles, Graham, G1 aGudnason, Vilmundur1 aHelmer, Catherine1 aHodge, Allison1 aJackson, Rebecca1 aKhaw, Kay-Tee1 aLaakso, Markku1 aLai, Heidi1 aLaurin, Danielle1 aLeander, Karin1 aLindsay, Joan1 aMicha, Renata1 aMursu, Jaako1 aNinomiya, Toshiharu1 aPost, Wendy1 aPsaty, Bruce, M1 aRiserus, Ulf1 aRobinson, Jennifer, G1 aShadyab, Aladdin, H1 aSnetselaar, Linda1 aSala-Vila, Aleix1 aSun, Yangbo1 aSteffen, Lyn, M1 aTsai, Michael, Y1 aWareham, Nicholas, J1 aWood, Alexis, C1 aH Y Wu, Jason1 aHu, Frank1 aSun, Qi1 aSiscovick, David, S1 aLemaitre, Rozenn, N1 aMozaffarian, Dariush1 aFatty Acids and Outcomes Research Consortium (FORCE) uhttps://chs-nhlbi.org/node/877705367nas a2201033 4500008004100000022001400041245012400055210006900179260001600248300001200264490000800276520243900284653002502723653002502748653002902773653001102802653001602813653002402829653003302853653001702886100002102903700002002924700001802944700002002962700001802982700001903000700002203019700001603041700002003057700002703077700002603104700002403130700001703154700002103171700002203192700002403214700002103238700002103259700002503280700001803305700002003323700001803343700002503361700003103386700002303417700002003440700002203460700001903482700002303501700002203524700002303546700002403569700002003593700002003613700002503633700002303658700002103681700002303702700002603725700001703751700002203768700002603790700002303816700002103839700002103860700002003881700001903901700002003920700001803940700001503958700001703973700001203990700002104002700001904023700001704042700001504059700002204074700002104096700002204117700001604139700001804155700001804173700001904191700002004210700002404230700002504254700001804279856003604297 2023 eng d a1756-183300aAssociation of omega 3 polyunsaturated fatty acids with incident chronic kidney disease: pooled analysis of 19 cohorts.0 aAssociation of omega 3 polyunsaturated fatty acids with incident c2023 Jan 18 ae0729090 v3803 aOBJECTIVE: To assess the prospective associations of circulating levels of omega 3 polyunsaturated fatty acid (n-3 PUFA) biomarkers (including plant derived α linolenic acid and seafood derived eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid) with incident chronic kidney disease (CKD).
DESIGN: Pooled analysis.
DATA SOURCES: A consortium of 19 studies from 12 countries identified up to May 2020.
STUDY SELECTION: Prospective studies with measured n-3 PUFA biomarker data and incident CKD based on estimated glomerular filtration rate.
DATA EXTRACTION AND SYNTHESIS: Each participating cohort conducted de novo analysis with prespecified and consistent exposures, outcomes, covariates, and models. The results were pooled across cohorts using inverse variance weighted meta-analysis.
MAIN OUTCOME MEASURES: Primary outcome of incident CKD was defined as new onset estimated glomerular filtration rate <60 mL/min/1.73 m. In a sensitivity analysis, incident CKD was defined as new onset estimated glomerular filtration rate <60 mL/min/1.73 m and <75% of baseline rate.
RESULTS: 25 570 participants were included in the primary outcome analysis and 4944 (19.3%) developed incident CKD during follow-up (weighted median 11.3 years). In multivariable adjusted models, higher levels of total seafood n-3 PUFAs were associated with a lower incident CKD risk (relative risk per interquintile range 0.92, 95% confidence interval 0.86 to 0.98; P=0.009, I=9.9%). In categorical analyses, participants with total seafood n-3 PUFA level in the highest fifth had 13% lower risk of incident CKD compared with those in the lowest fifth (0.87, 0.80 to 0.96; P=0.005, I=0.0%). Plant derived α linolenic acid levels were not associated with incident CKD (1.00, 0.94 to 1.06; P=0.94, I=5.8%). Similar results were obtained in the sensitivity analysis. The association appeared consistent across subgroups by age (≥60 <60 years), estimated glomerular filtration rate (60-89 ≥90 mL/min/1.73 m), hypertension, diabetes, and coronary heart disease at baseline.
CONCLUSIONS: Higher seafood derived n-3 PUFA levels were associated with lower risk of incident CKD, although this association was not found for plant derived n-3 PUFAs. These results support a favourable role for seafood derived n-3 PUFAs in preventing CKD.
10aalpha-Linolenic Acid10aFatty Acids, Omega-310aFatty Acids, Unsaturated10aHumans10aMiddle Aged10aProspective Studies10aRenal Insufficiency, Chronic10aRisk Factors1 aOng, Kwok, Leung1 aMarklund, Matti1 aHuang, Liping1 aRye, Kerry-Anne1 aHui, Nicholas1 aPan, Xiong-Fei1 aRebholz, Casey, M1 aKim, Hyunju1 aSteffen, Lyn, M1 avan Westing, Anniek, C1 aGeleijnse, Johanna, M1 aHoogeveen, Ellen, K1 aChen, Yun-Yu1 aChien, Kuo-Liong1 aFretts, Amanda, M1 aLemaitre, Rozenn, N1 aImamura, Fumiaki1 aForouhi, Nita, G1 aWareham, Nicholas, J1 aBirukov, Anna1 aJäger, Susanne1 aKuxhaus, Olga1 aSchulze, Matthias, B1 ade Mello, Vanessa, Derenji1 aTuomilehto, Jaakko1 aUusitupa, Matti1 aLindström, Jaana1 aTintle, Nathan1 aHarris, William, S1 aYamasaki, Keisuke1 aHirakawa, Yoichiro1 aNinomiya, Toshiharu1 aTanaka, Toshiko1 aFerrucci, Luigi1 aBandinelli, Stefania1 aVirtanen, Jyrki, K1 aVoutilainen, Ari1 aJayasena, Tharusha1 aThalamuthu, Anbupalam1 aPoljak, Anne1 aBustamante, Sonia1 aSachdev, Perminder, S1 aSenn, Mackenzie, K1 aRich, Stephen, S1 aTsai, Michael, Y1 aWood, Alexis, C1 aLaakso, Markku1 aLankinen, Maria1 aYang, Xiaowei1 aSun, Liang1 aLi, Huaixing1 aLin, Xu1 aNowak, Christoph1 aArnlöv, Johan1 aRiserus, Ulf1 aLind, Lars1 aLe Goff, Mélanie1 aSamieri, Cecilia1 aHelmer, Catherine1 aQian, Frank1 aMicha, Renata1 aTin, Adrienne1 aKöttgen, Anna1 ade Boer, Ian, H1 aSiscovick, David, S1 aMozaffarian, Dariush1 aWu, Jason, HY uhttps://chs-nhlbi.org/node/945604184nas a2200829 4500008004100000022001400041245017700055210006900232260001600301300001200317490000800329520172300337653001202060653001502072653002802087653002602115653002502141653001702166100002202183700002102205700002002226700001602246700001902262700002002281700002202301700001802323700001902341700002302360700002102383700002002404700002002424700002202444700002002466700002002486700001902506700002302525700002402548700002102572700002502593700001802618700002402636700002002660700002102680700002602701700002202727700001902749700001902768700001702787700002702804700002502831700001602856700002102872700002402893700001802917700002402935700002402959700001902983700002003002700002203022700002503044700002103069700002003090700002503110700001803135700002003153700002303173700002103196700002503217700001903242710005703261856003603318 2024 eng d a1524-453900aRole of Polyunsaturated Fat in Modifying Cardiovascular Risk Associated With Family History of Cardiovascular Disease: Pooled De Novo Results From 15 Observational Studies.0 aRole of Polyunsaturated Fat in Modifying Cardiovascular Risk Ass c2024 Jan 23 a305-3160 v1493 aBACKGROUND: It is unknown whether dietary intake of polyunsaturated fatty acids (PUFA) modifies the cardiovascular disease (CVD) risk associated with a family history of CVD. We assessed interactions between biomarkers of low PUFA intake and a family history in relation to long-term CVD risk in a large consortium.
METHODS: Blood and tissue PUFA data from 40 885 CVD-free adults were assessed. PUFA levels ≤25th percentile were considered to reflect low intake of linoleic, alpha-linolenic, and eicosapentaenoic/docosahexaenoic acids (EPA/DHA). Family history was defined as having ≥1 first-degree relative who experienced a CVD event. Relative risks with 95% CI of CVD were estimated using Cox regression and meta-analyzed. Interactions were assessed by analyzing product terms and calculating relative excess risk due to interaction.
RESULTS: After multivariable adjustments, a significant interaction between low EPA/DHA and family history was observed (product term pooled RR, 1.09 [95% CI, 1.02-1.16]; =0.01). The pooled relative risk of CVD associated with the combined exposure to low EPA/DHA, and family history was 1.41 (95% CI, 1.30-1.54), whereas it was 1.25 (95% CI, 1.16-1.33) for family history alone and 1.06 (95% CI, 0.98-1.14) for EPA/DHA alone, compared with those with neither exposure. The relative excess risk due to interaction results indicated no interactions.
CONCLUSIONS: A significant interaction between biomarkers of low EPA/DHA intake, but not the other PUFA, and a family history was observed. This novel finding might suggest a need to emphasize the benefit of consuming oily fish for individuals with a family history of CVD.
10aAnimals10aBiomarkers10aCardiovascular Diseases10aDocosahexaenoic Acids10aFatty Acids, Omega-310aRisk Factors1 aLaguzzi, Federica1 aÅkesson, Agneta1 aMarklund, Matti1 aQian, Frank1 aGigante, Bruna1 aBartz, Traci, M1 aBassett, Julie, K1 aBirukov, Anna1 aCampos, Hannia1 aHirakawa, Yoichiro1 aImamura, Fumiaki1 aJäger, Susanne1 aLankinen, Maria1 aMurphy, Rachel, A1 aSenn, Mackenzie1 aTanaka, Toshiko1 aTintle, Nathan1 aVirtanen, Jyrki, K1 aYamagishi, Kazumasa1 aAllison, Matthew1 aBrouwer, Ingeborg, A1 ade Faire, Ulf1 aEiriksdottir, Gudny1 aFerrucci, Luigi1 aForouhi, Nita, G1 aGeleijnse, Johanna, M1 aHodge, Allison, M1 aKimura, Hitomi1 aLaakso, Markku1 aRiserus, Ulf1 avan Westing, Anniek, C1 aBandinelli, Stefania1 aBaylin, Ana1 aGiles, Graham, G1 aGudnason, Vilmundur1 aIso, Hiroyasu1 aLemaitre, Rozenn, N1 aNinomiya, Toshiharu1 aPost, Wendy, S1 aPsaty, Bruce, M1 aSalonen, Jukka, T1 aSchulze, Matthias, B1 aTsai, Michael, Y1 aUusitupa, Matti1 aWareham, Nicholas, J1 aOh, Seung-Won1 aWood, Alexis, C1 aHarris, William, S1 aSiscovick, David1 aMozaffarian, Dariush1 aLeander, Karin1 aFatty Acids and Outcomes Research Consortium (FORCE) uhttps://chs-nhlbi.org/node/9587